Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Feb;38(2):396–399. doi: 10.1128/aac.38.2.396

Penetration of vancomycin into mediastinal and cardiac tissues in humans.

C Martin 1, M Alaya 1, M N Mallet 1, X Viviand 1, K Ennabli 1, R Said 1, P De Micco 1
PMCID: PMC284467  PMID: 8192475

Abstract

Vancomycin penetration into heart tissues (valves, myocardium, auricles, and pericardium) and mediastinal tissues (fat and sternal bone) was evaluated after two regimens of vancomycin administration. Ten patients were given 15 mg of vancomycin per kg of body weight before anesthesia. Ten other patients received the same dose and then a second 7.5-mg/kg dose at the time of initiation of cardiopulmonary bypass. Similar and satisfactory vancomycin tissue penetrations were observed in both groups. However, for some patients in the two groups, vancomycin levels in tissue were less than the MICs for potential pathogens (Staphylococcus aureus and Staphylococcus epidermidis).

Full text

PDF
396

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bayer A. S., Nelson R. J., Slama T. G. Current concepts in prevention of prosthetic valve endocarditis. Chest. 1990 May;97(5):1203–1207. doi: 10.1378/chest.97.5.1203. [DOI] [PubMed] [Google Scholar]
  2. Bergamini T. M., Polk H. C., Jr The importance of tissue antibiotic activity in the prevention of operative wound infection. J Antimicrob Chemother. 1989 Mar;23(3):301–313. doi: 10.1093/jac/23.3.301. [DOI] [PubMed] [Google Scholar]
  3. Burke J. F. The effective period of preventive antibiotic action in experimental incisions and dermal lesions. Surgery. 1961 Jul;50:161–168. [PubMed] [Google Scholar]
  4. Classen D. C., Evans R. S., Pestotnik S. L., Horn S. D., Menlove R. L., Burke J. P. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med. 1992 Jan 30;326(5):281–286. doi: 10.1056/NEJM199201303260501. [DOI] [PubMed] [Google Scholar]
  5. Dasta J. F., Jacobi J., Wu L. S., Sokoloski T., Beckley P., Reilley T. E., Howie M. B. Loss of nitroglycerin to cardiopulmonary bypass apparatus. Crit Care Med. 1983 Jan;11(1):50–52. doi: 10.1097/00003246-198301000-00013. [DOI] [PubMed] [Google Scholar]
  6. Farber B. F., Karchmer A. W., Buckley M. J., Moellering R. C., Jr Vancomycin prophylaxis in cardiac operations: determination of an optimal dosage regimen. J Thorac Cardiovasc Surg. 1983 Jun;85(6):933–935. [PubMed] [Google Scholar]
  7. Hoddinott C., Lovering A. M., Fernando H. C., Dixon J. H., Reeves D. S. Determination of bone and fat concentrations following systemic cefamandole and regional cefuroxime administration in patients undergoing knee arthroplasty. J Antimicrob Chemother. 1990 Dec;26(6):823–829. doi: 10.1093/jac/26.6.823. [DOI] [PubMed] [Google Scholar]
  8. Holley F. O., Ponganis K. V., Stanski D. R. Effect of cardiopulmonary bypass on the pharmacokinetics of drugs. Clin Pharmacokinet. 1982 May-Jun;7(3):234–251. doi: 10.2165/00003088-198207030-00004. [DOI] [PubMed] [Google Scholar]
  9. Kaiser A. B. Antimicrobial prophylaxis in surgery. N Engl J Med. 1986 Oct 30;315(18):1129–1138. doi: 10.1056/NEJM198610303151805. [DOI] [PubMed] [Google Scholar]
  10. Klamerus K. J., Rodvold K. A., Silverman N. A., Levitsky S. Effect of cardiopulmonary bypass on vancomycin and netilmicin disposition. Antimicrob Agents Chemother. 1988 May;32(5):631–635. doi: 10.1128/aac.32.5.631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Koren G., Crean P., Klein J., Goresky G., Villamater J., MacLeod S. M. Sequestration of fentanyl by the cardiopulmonary bypass (CPBP). Eur J Clin Pharmacol. 1984;27(1):51–56. doi: 10.1007/BF00553154. [DOI] [PubMed] [Google Scholar]
  12. Massias L., Dubois C., de Lentdecker P., Brodaty O., Fischler M., Farinotti R. Penetration of vancomycin in uninfected sternal bone. Antimicrob Agents Chemother. 1992 Nov;36(11):2539–2541. doi: 10.1128/aac.36.11.2539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mutch D., Richards G., Brown R. A., Mulder D. S. Bioactive antibiotic levels in the human aorta. Surgery. 1982 Dec;92(6):1068–1071. [PubMed] [Google Scholar]
  14. Pitkin D. H., Sachs C., Zajac I., Actor P. Distribution of sodium cefazolin in serum, muscle, bone marrow, and bone of normal rabbits. Antimicrob Agents Chemother. 1977 Apr;11(4):760–762. doi: 10.1128/aac.11.4.760. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Stanbridge T. N., Greenall D. J. Netilmicin prophylaxis in open-heart surgery. J Antimicrob Chemother. 1984 Jan;13 (Suppl A):59–65. doi: 10.1093/jac/13.suppl_a.59. [DOI] [PubMed] [Google Scholar]
  16. Stone H. H. Basic principles in the use of prophylactic antibiotics. J Antimicrob Chemother. 1984 Sep;14 (Suppl B):33–37. doi: 10.1093/jac/14.suppl_b.33. [DOI] [PubMed] [Google Scholar]
  17. Stratton C. W., Liu C., Weeks L. S. Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies. Antimicrob Agents Chemother. 1987 Aug;31(8):1210–1215. doi: 10.1128/aac.31.8.1210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Washington J. A., 2nd The effects and significance of subminimal inhibitory concentrations of antibiotics. Rev Infect Dis. 1979 Sep-Oct;1(5):781–786. doi: 10.1093/clinids/1.5.781. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES